Scott T. Tagawa, M.D.

Pivotal data published for sacituzumab govitecan in bladder cancer

“Sacituzumab govitecan is an active drug with a manageable safety profile with most common toxicities of neutropenia and diarrhea. Sacituzumab govitecan has notable efficacy compared with historical controls in pretreated mUC that has progressed on both prior platinum-based chemotherapy regimens and checkpoint inhibition,” principal investigator Scott T. Tagawa, MD, MS, FACP, professor of Medicine and Urology at Weill Cornell Medicine, an oncologist at New York-Presbyterian/Weill Cornell Medical Center, and coauthors wrote in their study conclusion.

Read more about Pivotal data published for sacituzumab govitecan in bladder cancer

Scott Tagawa, MD, on promising PSMA products in development for prostate cancer treatment

Dr. Tagawa, Medical Director of the Genitourinary Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, on promising PSMA products in development that look promising for the treatment of prostate cancer. Read More

Read more about Scott Tagawa, MD, on promising PSMA products in development for prostate cancer treatment

Weill Cornell Medicine Research Highlighted by Prostate Cancer Foundation’s “Top 5 Prostate Cancer Research Stories of 2017”

In January 2018, the Prostate Cancer Foundation recognized the developments of PSMA radionuclide therapy as one of the top 5 research stories of 2017, highlighting the recent work from Weill Cornell Medicine’s Department of Urology as a driving force behind this effort.

Read more about Weill Cornell Medicine Research Highlighted by Prostate Cancer Foundation’s “Top 5 Prostate Cancer Research Stories of 2017”

Prostate Cancer Foundation Announces 2017 PCF Challenge Awards to Accelerate the Development of New Treatments for Advanced Prostate Cancer

WASHINGTON, D.C., October 5, 2017 – The Prostate Cancer Foundation (PCF) today announced awards totaling $7.515 million to fund new 2017 PCF Challenge Awards supporting international, cross-disciplinary teams of investigators conducting pioneering research into critical, unmet medical needs in areas that have the highest potential for impacting and extending lives of men with advanced prostate cancer. This year’s awards include innovative research projects – such as testing several novel radiation-emitting prostate cancer-targeting treatments in advanced pr

Read more about Prostate Cancer Foundation Announces 2017 PCF Challenge Awards to Accelerate the Development of New Treatments for Advanced Prostate Cancer

First Clinical Trial of New Targeted Molecular Therapy in U.S. Takes Aim at Incurable Prostate Cancer

NewYork-Presbyterian and Weill Cornell Medicine clinicians in progress on Phase 1 clinical trial of PSMA-Targeted Therapeutic Agent for the Treatment for Metastatic Prostate Cancer

NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the U.S. that uses a small molecule, 177Lu-PSMA-617, to treat men with progressive prostate cancer that has spread beyond the prostate, or is metastatic, and is no longer responding to hormonal therapy.

Read more about First Clinical Trial of New Targeted Molecular Therapy in U.S. Takes Aim at Incurable Prostate Cancer